Actinium Pharmaceuticals (Actinium Pharmaceuticals) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Actinium Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2024 was $-7.39 Mil. Actinium Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Actinium Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Actinium Pharmaceuticals's current FCF Yield % is -13.61%.

The historical rank and industry rank for Actinium Pharmaceuticals's FCF Margin % or its related term are showing as below:

ATNM' s FCF Margin % Range Over the Past 10 Years
Min: -58627.16 Med: -1835.58 Max: 803.69
Current: -49037.04

During the past 13 years, the highest FCF Margin % of Actinium Pharmaceuticals was 803.69%. The lowest was -58627.16%. And the median was -1835.58%.

ATNM's FCF Margin % is ranked worse than
96.66% of 1048 companies
in the Biotechnology industry
Industry Median: -144.01 vs ATNM: -49037.04

Actinium Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Actinium Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals FCF Margin % Chart

Actinium Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,835.58

803.69

-58,627.16

Actinium Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-9,246.91	-

Competitive Comparison of Actinium Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Actinium Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's FCF Margin % falls into.

Actinium Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Actinium Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-47.488	/	0.081
	=	-58,627.16 %

Actinium Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-7.385	/	0
	=	%

Actinium Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

7AY1:Germany

Address

275 Madison Avenue, 7th Floor, New York, NY, USA, 10016

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Executives

Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin	officer: VP, Finance and Corporate Dev.	955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig	officer: Chief Scientific Officer	21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell	director	521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty	director	643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur	officer: Chief Commercial Officer	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray	officer: Executive Vice President	14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center	10 percent owner	1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa	director	138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave	director, officer: President and CEO	4 WATER STREET, EDISON NJ 08820
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc	10 percent owner	C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd.	10 percent owner	C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000